Search

Your search keyword '"Rana, Zaker"' showing total 48 results
Start Over Author "Rana, Zaker" Search Limiters Peer Reviewed
48 results on '"Rana, Zaker"'

5. WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer

Author

Sutera, Philip, Deek, Matthew P., Van der Eecken, Kim, Shetty, Amol C., Chang, Jin Hee, Hodges, Theresa, Song, Yang, Verbeke, Sofie, Van Dorpe, Jo, Fonteyne, Valérie, De Laere, Bram, Mishra, Mark, Rana, Zaker, Molitoris, Jason, Ferris, Matthew, Ross, Ashley, Schaeffer, Edward, Roberts, Nicholas, Song, Daniel Y., DeWeese, Theodore, Pienta, Kenneth J., Antonarakis, Emmanuel S., Ost, Piet, and Tran, Phuoc T.

Published
2023
Full Text
View/download PDF

6. Radiation Therapy: Brachytherapy

Author

Rana, Zaker, Cox, Brett, Lee, Lucille, Potters, Louis, Rastinehad, Ardeshir R., editor, Siegel, David N., editor, Wood, Bradford J., editor, and McClure, Timothy, editor

Published
2021
Full Text
View/download PDF

10. Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer

Author

Sutera, Philip, primary, Shetty, Amol C., additional, Song, Yang, additional, Hodges, Theresa, additional, Hoang, Tung, additional, Rana, Zaker, additional, Pienta, Kenneth, additional, Feng, Felix, additional, Song, Daniel Y., additional, DeWeese, Theodore, additional, Gillessen, Silke, additional, Sweeney, Christopher, additional, James, Nicholas, additional, Attard, Gerhardt, additional, Deek, Matthew, additional, and Tran, Phuoc T., additional

Published
2023
Full Text
View/download PDF

12. Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer

Author

Sutera, Philip, primary, Song, Yang, additional, Van der Eecken, Kim, additional, Shetty, Amol C., additional, English, Keara, additional, Hodges, Theresa, additional, Chang, Jinhee, additional, Fonteyne, Valérie, additional, Rana, Zaker, additional, Ren, Lei, additional, Mendes, Adrianna A., additional, Lumen, Nicolaas, additional, Delrue, Louke, additional, Verbeke, Sofie, additional, De Man, Kathia, additional, Song, Daniel Y., additional, Pienta, Kenneth, additional, Feng, Felix Y., additional, Joniau, Steven, additional, Lotan, Tamara, additional, Lane, Barton, additional, Kiess, Ana, additional, Rowe, Steven, additional, Pomper, Martin, additional, DeWeese, Theodore, additional, Deek, Matthew, additional, Sweeney, Christopher, additional, Ost, Piet, additional, and Tran, Phuoc T., additional

Published
2023
Full Text
View/download PDF

13. Rare missense neuronal cadherin gene (CDH2) variants in specific obsessive-compulsive disorder and Tourette disorder phenotypes

Author

Moya, Pablo R, Dodman, Nicholas H, Timpano, Kiara R, Rubenstein, Liza M, Rana, Zaker, Fried, Ruby L, Reichardt, Louis F, Heiman, Gary A, Tischfield, Jay A, King, Robert A, Galdzicka, Marzena, Ginns, Edward I, and Wendland, Jens R

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Genetics, Anxiety Disorders, Brain Disorders, Serious Mental Illness, Neurosciences, Clinical Research, Mental Health, 2.1 Biological and endogenous factors, Aetiology, Mental health, Adult, Antigens, CD, Blotting, Western, Cadherins, DNA Mutational Analysis, Genotype, HEK293 Cells, Humans, Mutation, Missense, Obsessive-Compulsive Disorder, Phenotype, Psychiatric Status Rating Scales, Tourette Syndrome, Transfection, N-cadherin, CDH2, rare gene variants, canine compulsive disorder, obsessive-compulsive disorder, Tourette disorder, Clinical Sciences, Genetics & Heredity, Clinical sciences
Abstract

The recent finding that the neuronal cadherin gene CDH2 confers a highly significant risk for canine compulsive disorder led us to investigate whether missense variants within the human ortholog CDH2 are associated with altered susceptibility to obsessive-compulsive disorder (OCD), Tourette disorder (TD) and related disorders. Exon resequencing of CDH2 in 320 individuals identified four non-synonymous single-nucleotide variants, which were subsequently genotyped in OCD probands, Tourette disorder probands and relatives, and healthy controls (total N=1161). None of the four variants was significantly associated with either OCD or TD. One variant, N706S, was found only in the OCD/TD groups, but not in controls. By examining clinical data, we found there were significant TD-related phenotype differences between those OCD probands with and without the N845S variant with regard to the co-occurrence of TD (Fisher's exact test P=0.014, OR=6.03). Both N706S and N845S variants conferred reduced CDH2 protein expression in transfected cells. Although our data provide no overall support for association of CDH2 rare variants in these disorders considered as single entities, the clinical features and severity of probands carrying the uncommon non-synonymous variants suggest that CDH2, along with other cadherin and cell adhesion genes, is an interesting gene to pursue as a plausible contributor to OCD, TD and related disorders with repetitive behaviors, including autism spectrum disorders.

Published
2013

15. Prognostic impact of circulating tumor cells in oligometastatic hormone-sensitive prostate cancer following metastasis-directed therapy.

Author

Bazyar, Soha, primary, Sutera, Philip, additional, Phillips, Ryan, additional, Deek, Mathew Pierre, additional, Radwan, Noura, additional, Marshall, Catherine Handy, additional, Mishra, Mark V., additional, Rana, Zaker Hamid, additional, Molitoris, Jason K., additional, Kwok, Young, additional, Gupta, Santosh, additional, Tubbs, Alisa, additional, Wenstrup, Rick, additional, DeWeese, Theodore L., additional, Song, Daniel Y., additional, Feng, Felix Y, additional, Pienta, Kenneth J., additional, Antonarakis, Emmanuel S., additional, Kiess, Ana Ponce, additional, and Tran, Phuoc T., additional

Published
2023
Full Text
View/download PDF

16. Genomic determinants of patterns of failure in metachronous oligometastatic castration-sensitive prostate cancer.

Author

Sutera, Philip, primary, Van der Eecken, Kim, additional, Shetty, Amol, additional, Song, Yang, additional, Hodges, Theresa, additional, Verbeke, Sofie, additional, Van Dorpe, Jo, additional, Fonteyne, Valerie, additional, De Laere, Bram, additional, Mishra, Mark V., additional, Rana, Zaker Hamid, additional, Molitoris, Jason K., additional, Ferris, Matthew J., additional, Roberts, Nicholas J, additional, Song, Daniel Y., additional, DeWeese, Theodore L., additional, Pienta, Kenneth J., additional, Deek, Matthew, additional, Ost, Piet, additional, and Tran, Phuoc T., additional

Published
2023
Full Text
View/download PDF

17. Phase 2 randomized total eradication of metastatic lesions following definitive radiation to the prostate in de novo oligometastatic prostate cancer (TERPs) trial.

Author

Rana, Zaker Hamid, primary, Helie, Nicole, additional, Eggleston, Caitlin, additional, Baker, Kaysee, additional, Molitoris, Jason K., additional, Ferris, Matthew J., additional, Patel, Akshar, additional, Kwok, Young, additional, McAvoy, Sarah, additional, Kunaprayoon, Dan, additional, Hong, Jack J., additional, Deek, Matthew, additional, Sutera, Philip, additional, Deek, Rebecca A, additional, Bentzen, Soren, additional, Siddiqui, Minhaj, additional, Mannuel, Heather Dorothy, additional, Hussain, Arif, additional, Tran, Phuoc T., additional, and Mishra, Mark V., additional

Published
2023
Full Text
View/download PDF

19. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials

Author

Deek, Matthew P., primary, Van der Eecken, Kim, additional, Sutera, Philip, additional, Deek, Rebecca A., additional, Fonteyne, Valérie, additional, Mendes, Adrianna A., additional, Decaestecker, Karel, additional, Kiess, Ana Ponce, additional, Lumen, Nicolaas, additional, Phillips, Ryan, additional, De Bruycker, Aurélie, additional, Mishra, Mark, additional, Rana, Zaker, additional, Molitoris, Jason, additional, Lambert, Bieke, additional, Delrue, Louke, additional, Wang, Hailun, additional, Lowe, Kathryn, additional, Verbeke, Sofie, additional, Van Dorpe, Jo, additional, Bultijnck, Renée, additional, Villeirs, Geert, additional, De Man, Kathia, additional, Ameye, Filip, additional, Song, Daniel Y., additional, DeWeese, Theodore, additional, Paller, Channing J., additional, Feng, Felix Y., additional, Wyatt, Alexander, additional, Pienta, Kenneth J., additional, Diehn, Maximillian, additional, Bentzen, Soren M., additional, Joniau, Steven, additional, Vanhaverbeke, Friedl, additional, De Meerleer, Gert, additional, Antonarakis, Emmanuel S., additional, Lotan, Tamara L., additional, Berlin, Alejandro, additional, Siva, Shankar, additional, Ost, Piet, additional, and Tran, Phuoc T., additional

Published
2022
Full Text
View/download PDF

20. Genomic biomarkers to guide precision radiotherapy in prostate cancer

Author

Sutera, Philip, primary, Deek, Matthew P., additional, Van der Eecken, Kim, additional, Wyatt, Alexander W., additional, Kishan, Amar U., additional, Molitoris, Jason K., additional, Ferris, Matthew J., additional, Siddiqui, M. Minhaj, additional, Rana, Zaker, additional, Mishra, Mark V., additional, Kwok, Young, additional, Davicioni, Elai, additional, Spratt, Daniel E., additional, Ost, Piet, additional, Feng, Felix Y., additional, and Tran, Phuoc T., additional

Published
2022
Full Text
View/download PDF

24. Phase I Trial of Dose-Escalated Stereotactic Radiosurgery (SRS) Boost for Unfavorable Locally Advanced Oropharyngeal Cancer

Author

Vempati, Prashant, primary, Halthore, Aditya N., additional, Teckie, Sewit, additional, Rana, Zaker, additional, Gogineni, Emile, additional, Antone, Jeffrey, additional, Zhang, Honglai, additional, Marrero, Mihaela, additional, Beadle, Kristin, additional, Frank, Douglas K., additional, Aziz, Mohamed, additional, Paul, Doru, additional, and Ghaly, Maged M., additional

Published
2020
Full Text
View/download PDF

35. Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate Cancer

Author

Sutera, Philip, Song, Yang, Shetty, Amol C., English, Keara, Van der Eecken, Kim, Guler, Ozan Cem, Wang, Jarey, Cao, Yufeng, Bazyar, Soha, Verbeke, Sofie, Van Dorpe, Jo, Fonteyne, Valérie, De Laere, Bram, Mishra, Mark, Rana, Zaker, Molitoris, Jason, Ferris, Matthew, Kiess, Ana, Song, Daniel Y., DeWeese, Theodore, Pienta, Kenneth J., Barbieri, Christopher, Marchionni, Luigi, Ren, Lei, Sawant, Amit, Simone, Nicole, Berlin, Alejandro, Onal, Cem, Tran, Phuoc T., Ost, Piet, and Deek, Matthew P.

Abstract

For patients with metachronous oligometastatic castration-sensitive prostate cancer, tumor genomics may play a role in the mode of progression and pattern of failure after initial therapy for metastatic disease. Specifically, patients with TP53and RB1mutations have a higher likelihood of progression, and TP53, SPOP, and WNT pathway mutations may have a role in metastatic organotropism directing the likelihood of bone and visceral disease progression.

Published
2024
Full Text
View/download PDF

36. Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712

Author

Rana, Zaker, Kamran, Sophia C., Shetty, Amol C., Sutera, Philip, Song, Yang, Bazyar, Soha, Solanki, Abhishek A., Simko, Jeffry P., Pollack, Alan, McConkey, David, Kates, Max, Siddiqui, M. Minhaj, Hiken, Jeffrey, Earls, Jon, Messina, David, Mouw, Kent W., Miyamoto, David, Shipley, William U., Michaelson, M. Dror, Zietman, Anthony, Coen, John J., Dahl, Douglas M., Jani, Ashesh B., Souhami, Luis, Chang, Brian K., Lee, R. Jeffrey, Pham, Huong, Marshall, David T., Shen, Xinglei, Pugh, Stephanie L., Feng, Felix Y., Efstathiou, Jason A., Tran, Phuoc T., and Deek, Matthew P.

Abstract

A novel transcriptional profiling platform revealed that gene expression consistent with high immune-cell infiltration and of specific genes associated with T-cell infiltration or IFNγ signaling was correlated with better survival following chemoradiation for muscle-invasive bladder cancer.

Published
2024
Full Text
View/download PDF

46. Improved Irritative Voiding Symptoms 3 Years after Stereotactic Body Radiation Therapy for Prostate Cancer

Author

Rana, Zaker, primary, Cyr, Robyn A., additional, Chen, Leonard N., additional, Kim, Brian S., additional, Moures, Rudy A., additional, Yung, Thomas M., additional, Lei, Siyuan, additional, Collins, Brian T., additional, Suy, Simeng, additional, Dritschilo, Anatoly, additional, Lynch, John H., additional, and Collins, Sean P., additional

Published
2014
Full Text
View/download PDF

47. (P037) Treatment of Prognostically Favorable Peripheral Nerve Sheath Tumors: A Single-Institution Experience.

Author

Rana., Zaker H., Asher, David, Richardson, Martin, Spencer, Kelly, McAllister IV., William H., and Kersh, Ronald

Abstract

PURPOSE: Peripheral nerve sheath tumors account for 5% to 10% of all soft tissue sarcomas. Recent data show that tumor diameter < 5 cm and/or gross total resection reduces hazard for death. The aim of this study was to review presentation, acute toxicity, and morbidity associated with surgery and radiation in the treatment of these favorable peripheral nerve sheath tumors at our institution. METHODS: We retrospectively reviewed the data of 27 patients treated at our institution from February 2010 to June 2015. Ten patients received stereotactic body radiation therapy (SBRT) in 4–6 fractions, 16 received gross total resections, and 1 received both surgery and radiation. Baseline characteristics gathered included race, age at diagnosis, body mass index (BMI), site, histology, grade, previous therapy, RT dose, duration of treatment, time to diagnosis, and presenting symptoms. Outcomes recorded focused on acute toxicities, local control, and overall survival. Toxicities were graded according to the Common Terminology Criteria for Adverse Events version 4.0. RESULTS: The median age at diagnosis was 53 years (range: 20–87 yr), median BMI (body mass index, kg/m2) was 28.9, median interval from onset of symptoms to diagnosis was 10 months (range: 0–32 mo), and median tumor size was 2.8 cm (range: 1.3–4.7 cm). Presenting symptoms included 41% of patients with lumbosacral plexopathy, 19% with mononeuropathy, 11% with incidental finding on imaging, 11% with a vestibular disturbance, 7% with brachial plexopathy, 7% with a gait disturbance, and 4% with a hip deformity. Toxicities were low, with 89% of patients experiencing grade 0/1 toxicity and 11% experiencing grade 2 toxicity. The local recurrence rate was 21% after a median of 18 months. There was no significant difference in outcomes between surgical treatment and RT. CONCLUSION: Both surgery and radiation are very well tolerated treatment regimens with limited and manageable toxicity in favorable patients. Outcomes in patients with peripheral nerve sheath tumors < 5 cm are promising. [ABSTRACT FROM AUTHOR]

Published
2016

48. Outcomes in the radiosurgical management of metastatic spine disease.

Author

Kelley KD, Racareanu R, Sison CP, Gogineni E, Rana Z, Gandhi SV, Salas S, Wagner K, Latefi A, and Ghaly MM

Abstract

Purpose: Stereotactic body radiation therapy (SBRT) is a common treatment option for patients with metastatic tumors of the spine. The optimal treatment-, tumor-, and patient-specific characteristics necessary to achieve durable outcomes remain less well understood given the heterogeneous nature of the patient population this modality typically serves. The objective of this analysis was to better understand the determinants underlying SBRT spine treatment outcomes., Methods and Materials: A total of 127 patients with 287 spine tumors were treated between March 2010 and May 2015. The median total doses for single-fraction and hypofractionated courses of treatment were 16 Gy (range, 16-20 Gy) and 24 Gy (range, 16-40 Gy), respectively. Radiologic local control and numeric pain score data were measured, and univariate and multivariate analyses were done to determine factors predictive of treatment response., Results: Median follow-up was 5.9 months (range, 1-61 months). Radiologic local control was achieved in 84.7% of patients at 6 months and in 74.7% of patients at 1 year. Local control was found to be affected by the Spinal Instability Neoplastic Score, and was worse in patients with scores ≥7 (hazard ratio [HR]: 4.25; 95% confidence interval [CI], 1.57-11.51). Patients who required upfront surgical intervention to alleviate spinal cord compression, address mechanical spinal instability, or both had worse local control than those who did not require surgery (HR: 2.32; 95% CI, 1.04-5.17). Patients treated with a hypofractionated course compared with a single fraction had worse radiologic local control (HR: 2.63; 95% CI, 1.27-5.45). No patients developed radiation-induced myelitis after treatment, and the vertebral compression fracture rate was 9.1% after SBRT., Conclusions: Patients with potentially unstable spines or needing upfront spinal surgery before SBRT are less likely to achieve durable radiologic local control. Additionally, patients treated with single-fraction regimens have improved local control compared with those treated with hypofractionated radiation.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results